Gilead Sciences (NASDAQ:GILD) Insider Johanna Mercier Sells 28,000 Shares of Company Stock

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the sale, the insider directly owned 110,684 shares in the company, valued at $18,877,156.20. The trade was a 20.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Johanna Mercier also recently made the following trade(s):

  • On Thursday, October 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00.
  • On Tuesday, September 15th, Johanna Mercier sold 3,000 shares of Gilead Sciences stock. The stock was sold at an average price of $144.22, for a total transaction of $432,660.00.

Gilead Sciences Price Performance

GILD stock opened at $170.26 on Wednesday. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58. The firm has a 50-day moving average of $155.90 and a 200 day moving average of $142.09. The company has a market cap of $211.18 billion, a P/E ratio of -53.88 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. During the same period in the previous year, the firm posted $2.47 EPS. The business’s revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post -0.97 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 1.9%. The ex-dividend date is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently -103.80%.

Gilead Sciences News Roundup

These are some of the GILD news items that stood out recently:

  • Neutral Sentiment: Gilead executives appeared at the Jefferies and UBS healthcare conferences, but the provided headlines do not identify specific new guidance or announcements that would change the investment outlook. Jefferies conference transcript
  • Negative Sentiment: Barclays maintained an equal-weight/hold stance while raising its price target to $160, still below the $170.26 price cited in the stock-performance information. That gap highlights valuation risk after GILD’s strong run. Barclays rating
  • Negative Sentiment: A separate report said Zacks Research forecast lower earnings, adding a cautious estimate revision to the mix. Zacks earnings forecast

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently made changes to their positions in the business. Holistic Wealth Advisors LLC bought a new stake in shares of Gilead Sciences in the third quarter valued at about $328,000. HighMark Wealth Management LLC lifted its stake in Gilead Sciences by 34.1% in the third quarter. HighMark Wealth Management LLC now owns 291 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 74 shares during the period. Ancora Advisors LLC lifted its stake in Gilead Sciences by 5.7% in the third quarter. Ancora Advisors LLC now owns 128,449 shares of the biopharmaceutical company’s stock worth $19,145,000 after acquiring an additional 6,984 shares during the period. Capstone Financial Advisors Inc. bought a new position in Gilead Sciences during the 3rd quarter worth about $224,000. Finally, Allworth Financial LP grew its holdings in Gilead Sciences by 10.9% during the 3rd quarter. Allworth Financial LP now owns 52,348 shares of the biopharmaceutical company’s stock worth $7,802,000 after acquiring an additional 5,156 shares in the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on GILD. Bank of America upped their price target on Gilead Sciences from $168.00 to $172.00 and gave the stock a “buy” rating in a research note on Tuesday, October 20th. Zacks Research lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 29th. BMO Capital Markets reissued an “outperform” rating and set a $184.00 price objective on shares of Gilead Sciences in a research report on Friday, October 30th. Morgan Stanley boosted their target price on shares of Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Finally, Wells Fargo & Company upped their target price on shares of Gilead Sciences from $165.00 to $190.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. Twenty-three research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus target price of $171.63.

Check Out Our Latest Analysis on GILD

Gilead Sciences Company Profile

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Articles

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.